The impact of the use of metformine for obese pregnant women in prevention

Keywords: obesity, pregnancy, metformin, preeclampsia


Aims: The article aims to evaluate the use of metformin in obese pregnant women in the prevention of pre-eclampsia.
Methods: This is a randomized clinical trial with obese pregnant women with a body mass index greater than or equal to 30 kg / m2 divided into two groups: a study group that used metformin and a control group that followed the prenatal routine. The pregnant women entered the study with gestational age less than 20 weeks and were followed throughout the prenatal period. The diagnosis of pre-eclampsia was made according to World Health Organization criteria.
Results: The absolute risk reduction and number needed to treat in a 95% confidence interval for the preeclampsia result were checked. In the results, 272 pregnant women were evaluated. In the study group (n = 127) eight (6.3%) developed preeclampsia, in the control group (n = 145) 31 (21.4%) obtained the disease (p <0.01).
Conclusions: The study indicated an absolute risk reduction of 15.1 times (95% CI: 7.1-22.9) and number needed to treat of 7 (95%CI: 4.4-13.9). The use of 1000 milligrams daily metformin indicated a 15.1 x reduction in the absolute risk of preeclampsia in the study population, with the need to treat seven pregnant women to avoid an outcome.


Download data is not yet available.


Costa AAR, Ribas MSSS, Amorim MMR SL. Mortalidade materna na cidade do Recife. Rev Bras Ginecol Obs 2002;24(7):455-62.

Adamo KB, Ferraro ZM, Goldfield G, Keely E, Stacey D, Hadjiyannakis S, Jean-Philippe S, Walker M, Barrowman NJ. The Maternal Obesity Management (MOM) Trial Protocol: a lifestyle intervention during pregnancy to minimize downstream obesity. Contemp Clin Trials 2013; 35(1):87-96.

World Health Organization. WHO Recommendations for Prevention and Treatment of Pre-Eclampsia and Eclampsia [monograph on the Internet]. WHO: Geneva, Switzerland; 2011. [cited 2020 Mar 20]. Available from:

Samiento-Piña M, Reyna-Villasmil E, Mejia-Montilla J, Santos-Bolívar J, Torres-Cepeda D, Reyna-Villasmil N. Valor predictivo de la proteinuria en 24 horas en la resultante neonatal de las preeclámpsicas. Clin Invest Ginecol Obstet 2017;44(3):119-124.

Nucci LB, Duncan BB, Mengue SS, Branchtein L, Shimidt MI FET. Assessment of weight gain during pregnancy in general prenatal care services in Brazil Avaliação de ganho ponderal intra-gestacional em serviços de assistência pré-natal no Brasil. Methods. Cad. Saúde Pública 2001;17(6):1367-74.

Stulbach TE, Benício MHD, Andreazza R, Kono S. Determinantes do ganho ponderal excessivo durante a gestação em serviço público de pré-natal de baixo risco. Rev Bras Epidemiol 2007;10:99-108.

Barton JR Sibai BM. Prediction and prevention of recurrent preeclampsia. Obstet Gynecol. Obs Gynecol 2008; 112:259-72.

Bianco-Miotto T, Blundell C, Buckberry S, Chamley L, Chong S, Cottrell E, Dawson P, Hanna C, Holland O, Lewis RM, Moritz K, Myatt L, Perkins AV, Powell T, Saffery R, Sferruzzi-Perri A, Sibley C, Simmons D, O’Tierney-Ginn PF. IFPA meeting 2015 workshop report I: placental mitochondrial function, transport systems and epigenetics. Placenta 2016;48:3-6.

Romero R, Erez O, Huttemann M, Panaitescu B, Conde-agudelo A, Pacora, P, Yoon BH, Grossman LI. Metformin, the aspirin of the 21st century: its role in gestational diabetes, prevention of preeclampsia and cancer, and the promotion of longevity. Am J Obs Gynecol 2017; 217(3):282-302.

Dempsey JC, Williams M A., Leisenring WM, Shy K, Luthy DA. Maternal birth weight in relation to plasma lipid concentrations in early pregnancy. Am J Obstet Gynecol 2004; 190:1359-68.

Silva JC, Amaral AR, Ferreira B da S, Petry Silva MR, Krelling PC. Obesidade durante a gravidez: resultados adversos da gestação e do parto. Rev. Bras. Ginecol. Obstet 2014; 36(11):509-13.

Syngelaki A, Nicolaides KH, Balani J, Hyer S, Akolekar R, Kotecha R, Pastides A, Shehata H. Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus. N Engl J Med 2016; 374(1):434-43.

Sibai BM. Hypertensive disorders of pregnancy: the United States perspective. Curr Opin Obstet Gynecol 2008; 20(2):102-06.

Askie LM, Duley L, Henderson-Smart DJ, Stewart LA, PARIS Collaborative Group. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 2007; 369(9575):1791- 98.

Rowan JA, Hague WM, Gao W, Battin MR, Moore MP. Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med 2008; 358(19):2003-15.

Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c332.

BRASIL. Ministério da Saúde. Secretaria de Atenção à Saúde. Departamento de Ações Programáticas Estratégicas. Gestação de alto risco: manual técnico [[monograph on the Internet]. 5. ed. Brasília: Editora

do Ministério da Saúde; 2012a. [cited 2020 Mar 2]. Available from:

Chiswick C, Reynolds RM, Denison F, Drake AJ, Forbes S, Newby DE, Walker BR, Quenby S, Wray S, Weeks A, Lashen H, Rodriguez A, Murray G, Whyte S, Norman JE. Effect of metformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2015;3(10):778-86.

Battaglia FC, Lubchenco LO. A practical classification of newborn infants by weight and gestational age. J Pediatr 1967;71(2):159-63.

Fletcher RH, Fletcher SW, Fletcher GS. Epidemiologia clínica: elementos essenciais. 5.ed. Porto Alegre: ArtMed; 2014.

Salihu HM, Lynch O, Alio AP, Kornosky JL, Clayton HB, Mbah AK. Extreme obesity and risk of placental abruption. Hum Reprod 2009; 24(2):438-44.

Chang JJ, Muglia LJ, Macones GA. Association of early-onset preeclampsia. In first pregnancy with normotensive second pregnancy outcomes: a population based study BJOG 2010;117(8):946-53.

Reis ZSN, Lage EM, Teixeira PG, Porto LB, Guedes LR, Oliveira ECL, Cabral ACV. Pré-eclâmpsia precoce e tardia: uma classificação mais adequada para o prognóstico materno e perinatal? Rev Bras Ginecol e Obs 2010;32(12):584-90.

Zhao PL, Sheng XY, Zhou S, Yang T, Ma LY, Zhou Y, Cui YM. Metformin versus insulin for gestational diabetes mellitus: a meta-analysis. Br J Clin Pharmacol 2015; 80(5):1224-34.

Fujita D, Tanabe A, Sekijima T, Soen H, Narahara K, Yamashita Y, Soen H, Narahara K, Yamashita Y, Terai Y, Kamegai H, Ohmichi M. Role of extracellular signal-regulated kinase and AKT cascades in regulating hypoxia-induced angiogenic factors produced by a trophoblast-derived cell line. J Endocrinol. 2010; 206:131-40.

Couto AA. Farmacologia Cardiovascular Aplicada à Clínica. ed. Revinter2a edição, Rio de Janeiro; 1998.

Bouchoucha M, Uzzan B, Cohen, R. Metformin and digestive disorders. Diabetes & Metabolism. 2011;37(2):90- 96.

Roberge S, Nicolaides K, Demers S, Hyett j, Chaillet N, Bujold E. The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. Am J Obstet Gynecol. 2017; 216(2):110-20.

Norgard B, Puhó E, Czeizel AE, Skriver MV, Sorensen HT. Aspirin use during early pregnancy an the risk of congenital abnormalities: a population-based case- control study. Am J Obstet Gynecol. 2005;192:922-3.

Coomarasamy A, Honest H, Papaidannou S, Gee H, Khan KS. Aspirin for prevention of preeclampsia in women with historical risk factors: a systematic review. Obstet Gynecol. 2003; 101:1319-32.

Briggs GG, Freeman RK, Yaffe SJ. (editors.). Drugs in pregnancy and lactation. 6th ed. Philadelphia: Lippincot Williams & Wilkins; 2002.

Macedo PHG. Estudo morfológico de fetos e placentas de ratas sob a ação do etanol e/ou ácido acetilsalicílico [tese]. São Paulo: Universidade Federal de São Paulo, Escola Paulista de Medicina; 1998.

Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev [Internet]. 2007;[cited 2020 Mar 02];18(2). CD004659. Available from:

Rolnik DL, Wright D, Poon LCY, Syngelaki A, O’Gorman N, de Paco Matallana C. ASPRE trial: performance of screening for preterm pre-eclampsia. Ultrasound Obstet Gynecol. 2017;50(4):492-95.

Marchetti P, Del Guerra S, Marselli L, Lupi R, Masini M, Pollera M, Boggi U, Vistoli F, Del Prado FM. Pancreatic islets from type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by metformin. J Clin Endocrinol Metab.2004; 89(11):5535-41.

How to Cite
do Nascimento, I. B., Sales, W. B., Dienstmann, G., de Souza, M. L. R., Fleig, R., & Silva, J. C. (2020). The impact of the use of metformine for obese pregnant women in prevention. Scientia Medica, 30(1), e35338.
Original Articles